Aegerion Pharmaceuticals, Inc. clinical trials
Acquired by Chiesi Farmaceutici S.p.A., Apr 12, 2023 · source ↗
The registry lists 17 studies whose lead sponsor is Aegerion Pharmaceuticals, Inc.. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Nov 26, 2025.
Before and after it joined Chiesi Farmaceutici S.p.A.
- First submitted before Aegerion Pharmaceuticals, Inc. became part of Chiesi Farmaceutici S.p.A.
- 17
- First submitted after Aegerion Pharmaceuticals, Inc. became part of Chiesi Farmaceutici S.p.A.
- 0
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
Status
- Completed
- 15
- Withdrawn
- 2
Registry sponsor names on this page
- Aegerion Pharmaceuticals, Inc.17 studies
Something wrong with this grouping? Tell us on the Chiesi Farmaceutici S.p.A. page.
Studies
Recruiting first, then most recently updated. Showing 17 of 17. All Chiesi Farmaceutici S.p.A. studies →
- Immunogenicity of Metreleptin in Patients With Generalized LipodystrophyCompletedNCT04026178Phase 4
Sponsor listed in the registry: Aegerion Pharmaceuticals, Inc. · First submitted before Aegerion Pharmaceuticals, Inc. became part of Chiesi Farmaceutici S.p.A.
- Study to Determine the Intra-subject Variability of Pharmacokinetics of Lomitapide in Healthy SubjectsCompletedNCT01915771Phase 1
Sponsor listed in the registry: Aegerion Pharmaceuticals, Inc. · First submitted before Aegerion Pharmaceuticals, Inc. became part of Chiesi Farmaceutici S.p.A.
- Evaluate the Effect of Atorvastatin on the Pharmacokinetics of Lomitapide in Healthy Subjects.CompletedNCT02080455Phase 1
Sponsor listed in the registry: Aegerion Pharmaceuticals, Inc. · First submitted before Aegerion Pharmaceuticals, Inc. became part of Chiesi Farmaceutici S.p.A.
- Evaluate the Effect of Ethinyl Estradiol/Norgestimate on the Pharmacokinetics of Lomitapide in Healthy Female SubjectsCompletedNCT02080468Phase 1
Sponsor listed in the registry: Aegerion Pharmaceuticals, Inc. · First submitted before Aegerion Pharmaceuticals, Inc. became part of Chiesi Farmaceutici S.p.A.
- Phase I Study of the Safety, Tolerability, PK & PD of Lomitapide in Japanese and Caucasian Subjects With Elevated LDL-CCompletedNCT01760187Phase 1
Sponsor listed in the registry: Aegerion Pharmaceuticals, Inc. · First submitted before Aegerion Pharmaceuticals, Inc. became part of Chiesi Farmaceutici S.p.A.
- Efficacy and Safety of Lomitapide in Japanese Patients With HoFH on Concurrent Lipid-Lowering TherapyCompletedNCT02173158Phase 3
Sponsor listed in the registry: Aegerion Pharmaceuticals, Inc. · First submitted before Aegerion Pharmaceuticals, Inc. became part of Chiesi Farmaceutici S.p.A.
- Long Term, Follow-on Study of Lomitapide in Patients With Homozygous Familial HypercholesterolemiaCompletedNCT00943306Phase 3
Sponsor listed in the registry: Aegerion Pharmaceuticals, Inc. · First submitted before Aegerion Pharmaceuticals, Inc. became part of Chiesi Farmaceutici S.p.A.
- AEGR-733 and Atorvastatin 20 mg vs. Monotherapy in Moderate HypercholesterolemiaCompletedNCT00474240Phase 2
Sponsor listed in the registry: Aegerion Pharmaceuticals, Inc. · First submitted before Aegerion Pharmaceuticals, Inc. became part of Chiesi Farmaceutici S.p.A.
- A Safety and Efficacy Study of AEGR-733 to Treat Homozygous Familial Hypercholesterolemia (FH)CompletedNCT00730236Phase 3
Sponsor listed in the registry: Aegerion Pharmaceuticals, Inc. · First submitted before Aegerion Pharmaceuticals, Inc. became part of Chiesi Farmaceutici S.p.A.
- Evaluate Low Doses of AEGR-733 on Hepatic Fat Accumulation by MRSCompletedNCT00559962Phase 2
Sponsor listed in the registry: Aegerion Pharmaceuticals, Inc. · First submitted before Aegerion Pharmaceuticals, Inc. became part of Chiesi Farmaceutici S.p.A.
- Pharmacokinetic Drug Interactions of AEGR-733 on Lipid-lowering AgentsCompletedNCT00359281Phase 2
Sponsor listed in the registry: Aegerion Pharmaceuticals, Inc. · First submitted before Aegerion Pharmaceuticals, Inc. became part of Chiesi Farmaceutici S.p.A.
- Evaluate Safety and Efficacy of AEGR-733 and Atorvastatin vs Atorvastatin Monotherapy in HypercholesterolemiaCompletedNCT00690443Phase 2
Sponsor listed in the registry: Aegerion Pharmaceuticals, Inc. · First submitted before Aegerion Pharmaceuticals, Inc. became part of Chiesi Farmaceutici S.p.A.
- Evaluate the Efficacy and Safety of Lomitapide in Pediatric Patients With Homozygous Familial Hypercholesterolemia on Stable Lipid-lowering TherapyWithdrawnNCT02765841Phase 3
Sponsor listed in the registry: Aegerion Pharmaceuticals, Inc. · First submitted before Aegerion Pharmaceuticals, Inc. became part of Chiesi Farmaceutici S.p.A.
- A Comparative Bioavailability Study of Lomitapide 20 mg Intact vs SprinkledCompletedNCT02044419Phase 1
Sponsor listed in the registry: Aegerion Pharmaceuticals, Inc. · First submitted before Aegerion Pharmaceuticals, Inc. became part of Chiesi Farmaceutici S.p.A.
- Effects of Lomitapide on Carotid and Aortic AtherosclerosisWithdrawnNCT02399852
Sponsor listed in the registry: Aegerion Pharmaceuticals, Inc. · First submitted before Aegerion Pharmaceuticals, Inc. became part of Chiesi Farmaceutici S.p.A.
- The Safety & Efficacy of Combination BMS-201038 (AEGR-733) & Ezetimibe vs. Monotherapy in Moderate HypercholesterolemiaCompletedNCT00405067Phase 2
Sponsor listed in the registry: Aegerion Pharmaceuticals, Inc. · First submitted before Aegerion Pharmaceuticals, Inc. became part of Chiesi Farmaceutici S.p.A.
- Safety, Tolerability and Efficacy of Microsomal Triglyceride Protein (MTP) InhibitorCompletedNCT01556906Phase 2
Sponsor listed in the registry: Aegerion Pharmaceuticals, Inc. · First submitted before Aegerion Pharmaceuticals, Inc. became part of Chiesi Farmaceutici S.p.A.